Extended adjuvant therapy with neratinib plus fulvestrant blocks ER/HER2 crosstalk and maintains complete responses of ER+/HER2+ breast cancers: Implications to the ExteNET trial

類似資料

• Hyperactivation of TORC1 drives resistance to the pan-HER tyrosine kinase inhibitor neratinib in HER2-mutant cancers
  著者:: Sudhan, Dhivya R., 等
  出版事項: (2020)
• Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers
  著者:: Sudhan, Dhivya R., 等
  出版事項: (2020)
• Combined blockade of activating ERBB2 mutations and ER results in synthetic lethality of ER+/HER2 mutant breast cancer
  著者:: Croessmann, Sarah, 等
  出版事項: (2018)
• PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial
  著者:: Chia, Stephen K. L., 等
  出版事項: (2019)
• Patterns of occurrence and implications of neratinib-associated diarrhea in patients with HER2-positive breast cancer: analyses from the randomized phase III ExteNET trial
  著者:: Mortimer, Joanne, 等
  出版事項: (2019)